ARTICLE | Clinical News

HinsBet BioChaperone insulin: Phase IIa data

February 9, 2015 8:00 AM UTC

A double-blind, crossover Phase IIa trial in 36 Type I diabetics showed that a single 0.2 U/kg dose of HinsBet met the primary endpoint of improving the rate of early insulin exposure vs. a single 0.2...